Novel Stem Cell Therapy From Cellonis Biotechnologies Can Help Children With Diabetes Get Back Their Normal Lives
Cellonis Biotechnologies has recorded some remarkable results in the treatment of a twelve-year-old boy with diabetes using their stem cell therapy in a Beijing partner hospital. He has completely regained his normal life, enjoying sports and school activities just like every other person his age, and has been free from injections and drugs for more than half a year.
The boy's doctor during the treatment, Dr. Shi, is similarly satisfied. "The efficacy of our patient's treatment surprised me a lot," she commented. "He hasn't taken insulin injections for eight months, and so does not need to worry about his blood glucose during PE. Also, diabetes can stunt a child's growth, with diabetic children being smaller and weaker than other children, but he has grown more than 10 cm during this last half year. This is excellent news."
"Stem cell treatment is a new hope for diabetes sufferers," Dr. Shi continued. "It can replace dysfunctional pancreatic cells, getting to the root of the disease. Stem cell treatment, both for diabetes and for many other diseases, represents a new age for medicine."
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.